PRESS RELEASE
News
-
-
PRESS RELEASE
Unlocking Product Validation: Bioz and CE Elantech Set a New Standard for Success in Scientific Research
Bioz, Inc., a leading AI software company, announces its partnership with CE Elantech, a reputable lab tech supplier. Through this alliance, Bioz has integrated its digital widgets onto CE Elantech's product webpages, providing researchers with comprehensive application data to support informed decision-making. The Bioz Badges display structured product details and validation data, aiming to optimize scientific experimentation and discovery for CE Elantech's customers. This strategic alliance is set to empower researchers with confidence and inspire innovation. -
PRESS RELEASE
PUMA’s 2023 financial performance impacted by extraordinary Argentine peso devaluation
PUMA SE reports on its 2023 financial performance, revealing an impact from the extraordinary devaluation of the Argentine peso. The company achieved full-year outlook, despite the significant currency impact. The press release provides insights into the recorded financial performance, the expectations for 2024, and other relevant financial calendar events. -
PRESS RELEASE
EQS-Adhoc: PUMA SE: PUMA announces preliminary results for the financial year 2023 and outlook for 2024
PUMA SE announces preliminary results for the financial year 2023, revealing currency-adjusted sales growth and impact of extraordinary Argentine peso devaluation. The company also outlines its outlook for 2024, expecting mid-single-digit currency-adjusted sales growth and providing financial calendar dates for the year ahead. -
PRESS RELEASE
OHB signs contract for study to develop reconnaissance capabilities at European level
OHB System AG, a subsidiary of OHB SE, has signed a contract with the European Commission's DG DEFIS to conduct a study on developing new satellite-based reconnaissance capabilities at European level. The study aims to address the growing need for high-quality, exclusive, and reliable information to support decision-making in the EU, especially in light of global geopolitical challenges and the climate crisis. -
PRESS RELEASE
Original-Research: VOQUZ Labs AG (von NuWays AG): BUY
VOQUZ Labs AG has been upgraded from NuWays AG with a recommendation to buy. The company recently published strong 2023 order intake figures, indicating improved operations in the second half of the year. With a reassuring order intake and strong trading momentum, the company is expected to see sequential improvements in 2023 and return to double-digit top-line growth, positive EBITDA, and FCF generation in 2024. The compelling mid-term prospects and undemanding valuation indicate favorable investment potential. -
PRESS RELEASE
Original-Research: NFON AG (von NuWays AG): BUY
NFON AG, a German market leader in integrated business communication, has shown significant improvements in operational performance and efficiency. With the arrival of a new CEO, the company is on track to achieve profitability and positive free cash flow in 2024. The structural growth of the European cloud-PBX market and the implementation of cost-saving measures contribute to the company's positive outlook. Despite the recent decline in share price, NFON's valuation remains attractive, making it a recommended BUY with an increased PT of €11.70 based on DCF. -
PRESS RELEASE
Wolftank Group wins multi-million contract for new hydrogen filling station in South Tyrol
Wolftank Group, a leading technology partner for energy and environmental solutions, has won a multi-million euro contract for the planning and construction of a new hydrogen refueling station in Bolzano, South Tyrol. This facility will support the goal of modernizing the transportation fleet by providing refueling infrastructure for hydrogen-powered buses as well as 700-bar refueling system for cars and modern H2 trucks. The project reflects Wolftank's commitment to developing and implementing forward-looking technologies for sustainable mobility and decarbonization of transport. -
PRESS RELEASE
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Abivax, a clinical-stage biotechnology company, will host a virtual KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis on February 6, 2024. The event will feature discussions on the unmet medical need, current treatment landscape, and ongoing clinical development plans for obefazimod. The key speakers at the event will be Marla Dubinsky, MD, and Parambir Dulai, MD, who are both consultants for Abivax and members of the Steering Committee for the IBD Program. -
PRESS RELEASE
AUSTRIACARD HOLDINGS: A strong multinational technology company in payments & digital security
AUSTRIACARD HOLDINGS AG, a multinational technology company in the payments and digital security industry, has undergone significant growth, acquisitions, and financial performance in recent years. With a rich history dating back to 1897, the company has expanded its international presence and achieved impressive financial results, offering a combination of value and growth properties for investors.
